Format

Send to

Choose Destination
Lancet Infect Dis. 2019 Mar;19(3):233-234. doi: 10.1016/S1473-3099(19)30060-X.

Revolutionary new treatment regimens for multidrug-resistant tuberculosis.

Author information

1
Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, London WC1E 6BT, UK.
2
UCL Respiratory, Division of Medicine, University College London, London, UK; Royal Free London National Health Service Foundation Trust, London, UK.
3
Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, London WC1E 6BT, UK; National Institute for Health Research Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK. Electronic address: a.zumla@ucl.ac.uk.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center